Stefan Navarro, Experimental Biomedicine I / University Hospital Würzburg, GermanyGerman biotech spin-out Emfret Analytics GmbH & Co. KG has presented a first in class anticoagulant that helps preventing heart attacks and stroke while showing less adverse effects than approved meds.
ADVERTISEMENT
German biotech spin-out Emfret Analytics GmbH & Co. KG has presented a first in class anticoagulant that helps preventing heart attacks and stroke while showing less adverse effects than approved meds.